netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

IN THE FUTURE, ALZHEIMER’S MAY BE PREDICTED DURING EYE EXAMS

RPB-funded researchers at Washington University School of Medicine in St. Louis (WUSTL) have found a correlation in 30 older patients between retina thinning and elevated levels of tau and amyloid proteins that are the hallmark of Alzheimer’s disease.  They made their discovery by using optical coherence tomography angiography (OCTA) to examine the patients’ retinas. 

This first-of-its-kind research was published in August 23, 2018 in JAMA Ophthalmology.  The study was funded by an RPB Unrestricted Grant to the WUSTL Department of Ophthalmology. 

eye exam to screen for Alzheimer's

Gregory Van Stavern, MD, (seated) and Rajendra Apte, MD, PhD, examine a patient’s eyes, using technology to screen for Alzheimer's disease during an eye exam.

 

Photo credit: Matt Miller

Participants in the study were patients in The Memory and Aging Project at Washington University’s Knight Alzheimer’s Disease Research Center. About half of those in the study had elevated levels of amyloid or tau as found by PET scans or in cerebrospinal fluid.  This suggests that although they didn’t have symptoms, they likely would develop Alzheimer’s. In the other study subjects, PET scans and cerebrospinal fluid analyses were normal.

Of the patients studied, 17 had abnormal PET scans or lumbar punctures (to test cerebrospinal fluid), and all had retinal thinning and significant areas without blood vessels in the centers of their retinas.  Patients with normal PET scans and lumbar punctures had retinas that appeared normal.  

“In the patients with elevated levels of amyloid or tau, we detected significant thinning in the center of the retina,” said co-principal investigator Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences. “All of us have a small area devoid of blood vessels in the center of our retinas that is responsible for our most precise vision. We found that this zone lacking blood vessels was significantly enlarged in people with preclinical Alzheimer’s disease.”

The eye test used in the study, which is similar to technology found in many ophthalmologists’ offices, shines light into the eye, allowing the physician to measure retinal thickness, as well as thickness of the fibers in the optic nerve.  In this study, researchers added angiography, which allows physicians to distinguish red blood cells from other tissue in the retina.

Dr. Apte has been a recipient of the RPB Nelson Trust Award for Retinitis Pigmentosa (2016); the RPB Physician Scientist Award (2014); and the RPB Career Development Award (2004).  

While this was a preliminary study, Dr. Apte and colleagues believe that OCTA may become an inexpensive and noninvasive way to determine who should undergo more extensive Alzheimer’s testing.

READ THE FULL NEWS RELEASE FROM WUSTL

 

Related News: Feature Story, For the Media, Top Story

Giving Tuesday logo

RPB Supporters Save Sight on Giving Tuesday

We welcome your generosity to help us meet our goal!

Read More

 
Dr. Palczewski and lab members

An RPB Awardee Tackles Inherited Retinal Diseases

Dr. Krzysztof Palczewski develops and applies cutting-edge gene editing techniques to challenging genetic conditions.

Read More

 
Dr. David Calkins

RPB and Association of University Professors of Ophthalmology Announce 2023 Recipient of RPB David F. Weeks Award for Outstanding Vision Research

David J. Calkins, PhD, is recognized for ground-breaking contributions to the field of vision research.

Read More

 
RPB logo

Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Care

Award recipients to use the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) clinical database to improve care for all patients.

Read More

 
RPB logo

Grant from Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer

Research to Prevent Blindness and Castle Biosciences are partnering to provide new opportunities for medical students to pursue ocular cancer research.

Read More

 
RPB logo

New Glaucoma Research Grant Available

Research to Prevent Blindness and Aerie Pharmaceuticals are partnering to provide grant opportunities to support novel research in glaucoma.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.